Single-Cell and Plasma Proteomics Do Not Differentiate Patients With and Without SARS-CoV-2 Antigenemia in Convalescence in a Cohort of 100 Patients - Takeaways - MDSpire

Single-Cell and Plasma Proteomics Do Not Differentiate Patients With and Without SARS-CoV-2 Antigenemia in Convalescence in a Cohort of 100 Patients

  • By

  • Shaun Pienkos

  • Zoe Swank

  • Rebecca E Hamlin

  • Mallika Rao

  • Phillip Grant

  • Hector Bonilla

  • Karen Jacobson

  • Prasanna Jagannathan

  • Upinder Singh

  • David R Walt

  • Aruna Subramanian

  • Catherine Blish

  • August 26, 2025

  • 0 min

Share

  • 1

    The study analyzed plasma samples from 100 individuals at 3 and 12 months post-SARS-CoV-2 infection for antigen detection.

  • 2

    No significant differences in plasma proteins or immune cell protein expression were found between antigenemic and non-antigenemic patients.

  • 3

    Eighteen percent of participants showed detectable antigens at 3 months, while 14% did so at 12 months, with only 7.7% showing persistent antigenemia.

  • 4

    Rates of antigen detection were similar for patients with long COVID symptoms and those fully recovered at both 3 and 12 months.

  • 5

    The study found no significant differences in symptom categories between antigenemic and non-antigenemic participants after multiple comparisons.

Original Source(s)

Single-Cell and Plasma Proteomics Do Not Differentiate Patients With and Without SARS-CoV-2 Antigenemia in Convalescence in a Cohort of 100 Patients

  • by Shaun Pienkos, Zoe Swank, Rebecca E Hamlin, Mallika Rao, Phillip Grant, Hector Bonilla, Karen Jacobson, Prasanna Jagannathan, Upinder Singh, David R Walt, Aruna Subramanian, Catherine Blish

  • August 26, 2025

Related Content

Long-term epidemiological patterns of pediatric infectious diseases in an urban district of Shanghai, 2015–2023

Recent COVID-19 Shot Linked to Less Spread

Protection against spread appeared strongest within 6 months of vaccination, while exposed vaccinated contacts showed no measurable reduction in infection risk.

The CRISPR-powered Diagnostic SLEUTH

Novel DNA-guided system may support future RNA diagnostics and mutation detection

  • May 22, 2026

  • 2 min